Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
1.560
-0.080 (-4.88%)
At close: Feb 21, 2025, 4:00 PM
1.592
+0.032 (2.03%)
After-hours: Feb 21, 2025, 6:30 PM EST
Longeveron Employees
As of December 31, 2023, Longeveron had 24 total employees, including 23 full-time and 1 part-time employees. The number of employees increased by 3 or 14.29% compared to the previous year.
Employees
24
Change (1Y)
3
Growth (1Y)
14.29%
Revenue / Employee
$77,167
Profits / Employee
-$1,107,083
Market Cap
23.15M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 24 | 3 | 14.29% |
Dec 31, 2022 | 21 | 1 | 5.00% |
Dec 31, 2021 | 20 | 8 | 66.67% |
Dec 31, 2020 | 12 | -4 | -25.00% |
Dec 31, 2019 | 16 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
LGVN News
- 4 days ago - Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™ - GlobeNewsWire
- 2 months ago - Longeveron to Present at Biotech Showcase 2025 - GlobeNewsWire
- 2 months ago - Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024 - GlobeNewsWire
- 3 months ago - Longeveron, Inc. (LGVN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) - GlobeNewsWire
- 3 months ago - Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - GlobeNewsWire
- 4 months ago - Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) - GlobeNewsWire
- 4 months ago - Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting - GlobeNewsWire